<PAGE> 1
SCHEDULE 13G
(RULE 13d-102)
Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)
and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
ALLERGAN SPECIALTY THERAPEUTICS, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
CLASS A COMMON STOCK, $0.01 PAR VALUE PER SHARE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
018494104
- --------------------------------------------------------------------------------
(CUSIP Number)
DECEMBER 31, 1999
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act, but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP NO. 018494104 13G PAGE 2 OF 8 PAGES
- --------------------------------------------------------------------------------
1 Names of Reporting Persons/I.R.S. Identification Nos. of Above Persons
(Entities Only)
WOODBOURNE PARTNERS, L.P.
- --------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions) (b) [ ]
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
MISSOURI
- --------------------------------------------------------------------------------
Number of
5 Sole Voting Power
Shares -0-
-----------------------------------------------------
Beneficially 6 Shared Voting Power
-0-
Owned by -----------------------------------------------------
7 Sole Dispositive Power
Each -0-
-----------------------------------------------------
Reporting 8 Shared Dispositive Power
Person With -0-
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
264,600
- --------------------------------------------------------------------------------
10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
(See Instructions)
- --------------------------------------------------------------------------------
11 Percent of Class Represented by Amount in Row (9)
8.1%
- --------------------------------------------------------------------------------
12 Type of Reporting Person (See Instructions)
PN
- --------------------------------------------------------------------------------
<PAGE> 3
CUSIP NO. 018494104 13G PAGE 3 OF 8 PAGES
- --------------------------------------------------------------------------------
1 Names of Reporting Persons/I.R.S. Identification Nos. of Above Persons
(Entities Only)
FORSYTH JOINT VENTURE
- --------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions) (b) [ ]
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
MISSOURI
- --------------------------------------------------------------------------------
Number of
5 Sole Voting Power
Shares -0-
-----------------------------------------------------
Beneficially 6 Shared Voting Power
-0-
Owned by -----------------------------------------------------
7 Sole Dispositive Power
Each -0-
-----------------------------------------------------
Reporting 8 Shared Dispositive Power
Person With -0-
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
63,300
- --------------------------------------------------------------------------------
10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
(See Instructions)
- --------------------------------------------------------------------------------
11 Percent of Class Represented by Amount in Row (9)
1.9%
- --------------------------------------------------------------------------------
12 Type of Reporting Person (See Instructions)
00
- --------------------------------------------------------------------------------
<PAGE> 4
CUSIP NO. 018494104 13G PAGE 4 OF 8 PAGES
- --------------------------------------------------------------------------------
1 Names of Reporting Persons/I.R.S. Identification Nos. of Above Persons
(Entities Only)
CLAYTON MANAGEMENT COMPANY
- --------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions) (b) [ ]
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
MISSOURI
- --------------------------------------------------------------------------------
Number of
5 Sole Voting Power
Shares 327,900
-----------------------------------------------------
Beneficially 6 Shared Voting Power
-0-
Owned by -----------------------------------------------------
7 Sole Dispositive Power
Each 327,900
-----------------------------------------------------
Reporting 8 Shared Dispositive Power
Person With -0-
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
327,900
- --------------------------------------------------------------------------------
10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
(See Instructions)
- --------------------------------------------------------------------------------
11 Percent of Class Represented by Amount in Row (9)
10.0%
- --------------------------------------------------------------------------------
12 Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
<PAGE> 5
CUSIP NO. 018494104 13G PAGE 5 OF 8 PAGES
- --------------------------------------------------------------------------------
1 Names of Reporting Persons/I.R.S. Identification Nos. of Above Persons
(Entities Only)
JOHN D. WEIL
- --------------------------------------------------------------------------------
2 Check the Appropriate Box if a Member of a Group (a) [ ]
(See Instructions) (b) [ ]
- --------------------------------------------------------------------------------
3 SEC Use Only
- --------------------------------------------------------------------------------
4 Citizenship or Place of Organization
MISSOURI
- --------------------------------------------------------------------------------
Number of
5 Sole Voting Power
Shares 327,900
-----------------------------------------------------
Beneficially 6 Shared Voting Power
-0-
Owned by -----------------------------------------------------
7 Sole Dispositive Power
Each 327,900
-----------------------------------------------------
Reporting 8 Shared Dispositive Power
Person With -0-
- --------------------------------------------------------------------------------
9 Aggregate Amount Beneficially Owned by Each Reporting Person
327,900
- --------------------------------------------------------------------------------
10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]
(See Instructions)
- --------------------------------------------------------------------------------
11 Percent of Class Represented by Amount in Row (9)
10.0%
- --------------------------------------------------------------------------------
12 Type of Reporting Person (See Instructions)
IN
- --------------------------------------------------------------------------------
<PAGE> 6
CUSIP No. 018494104 13G Page 6 of 8 Pages
- --------------------------------------------------------------------------------
AMENDMENT NO. 2 TO SCHEDULE 13G
The Reporting Person reported the acquisition of shares of Class A
Common Stock, par value $.01 per share ("Stock"), of Allergan Specialty
Therapeutics, Inc., a Delaware corporation ("Issuer"), 2525 Dupont Drive,
Irvine, CA 92612, in an initial filing of this Schedule 13G on March 6, 1998, as
amended by Amendment No. 1 filed on February 16, 1999. In this regard, Item 4 is
hereby amended as follow. All other items are unchanged from the initial filing.
ITEM 4. Ownership.
<TABLE>
<CAPTION>
WOODBOURNE FORSYTH CLAYTON WEIL
---------- ------- ------- ----
<S> <C> <C> <C> <C>
(a) Amount beneficially owned: 264,600 63,300 327,900 327,900
(b) Percent of Class: 8.1% 1.9% 10.0% 10.0%
(c) Number of Shares as to which the
person has:
(i) Sole power to vote or direct
the vote: -0- -0- 327,900 327,900
(ii) Shared power to vote or direct
the vote: -0- -0- -0- -0-
(iii) Sole power to dispose or to
direct the disposition of: -0- -0- 327,900 327,900
(iv) Shared power to dispose or to direct
the disposition of:
-0- -0- -0- -0-
</TABLE>
<PAGE> 7
CUSIP No. 018494104 13G Page 7 of 8 Pages
- --------------------------------------------------------------------------------
ITEM 10. Certification.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
Dated: February 14, 2000 WOODBOURNE PARTNERS, L.P.,
by its General Partner, CLAYTON
MANAGEMENT COMPANY
/s/ John D. Weil
-----------------------------------
John D. Weil, President
Dated: February 14, 2000 FORSYTH JOINT VENTURE,
by its Manager, CLAYTON
MANAGEMENT COMPANY
/s/ John D. Weil
-----------------------------------
John D. Weil, President
Dated: February 14, 2000 CLAYTON MANAGEMENT COMPANY
/s/ John D. Weil
-----------------------------------
John D. Weil, President
Dated: February 14, 2000 /s/ John D. Weil
-----------------------------------
John D. Weil
<PAGE> 8
CUSIP No. 018494104 13G Page 8 of 8 Pages
- -------------------------------------------------------------------------------
EXHIBIT A TO SCHEDULE 13G
AGREEMENT PURSUANT TO RULE 13D-1(K)(1)
The undersigned persons, on February 14, 2000, agree and consent to the
joint filing on their behalf of this Amendment No. 2 to Schedule 13G in
connection with their beneficial ownership of the Class A Common Stock of
Allergan Specialty Therapeutics, Inc.
WOODBOURNE PARTNERS, L.P.,
by its General Partner, CLAYTON
MANAGEMENT COMPANY
/s/ John D. Weil
---------------------------------
John D. Weil, President
WOODBOURNE PARTNERS, L.P.,
by its Manager, CLAYTON
MANAGEMENT COMPANY
/s/ John D. Weil
---------------------------------
John D. Weil, President
CLAYTON MANAGEMENT COMPANY
/s/ John D. Weil
---------------------------------
John D. Weil, President
/s/ John D. Weil
---------------------------------
John D. Weil
